Jun 23, 2023 at 8:30 AM CEST. Oral Presentation: OS-063 Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Presenter: Stephen A. Harrison, MD ...Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.Aug 10, 2023 · Jun 23, 2023 at 8:30 AM CEST. EASL International Liver Congress™ 2023. Oral Presentation: OS-063 Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Prior to joining Altimmune, Dr. Georges co-founded Immune Targeting Systems (ITS) Limited and served as the chief technology officer from 2004 until its acquisition by Altimmune in March 2015. Prior to ITS, Dr. Georges served as the of head of immunology at SEDAC-Therapeutics from 1999 until 2003. He received his Ph.D. in Molecular Immunology ... Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX ...Jul 11, 2023 · JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Altimmune ( ALT – Research Report) today and set a price target of $15.00. The company’s shares closed yesterday at $3.38 ... Altimmune expects to commence patient enrollment in the Phase 1 clinical trial in the coming week. “We believe deployment of intranasal vaccines like AdCOVID will be essential to a successful global response to the pandemic,” said Vipin K. Garg, President and Chief Executive Officer of Altimmune. “FDA clearance of the IND marks an ...Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.Pemvidutide is a novel, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH). Pemvidutide incorporates the EuPort TM domain, a proprietary technology that increases the serum half-life of pemvidutide, allowing for weekly dosing, and may slow the entry of ... Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.Sep 28, 2021 · Altimmune to host a conference call today at 8:30 am EST GAITHERSBURG, Md. , Sept. 28, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemvidutide (proposed INN, formerly known as ALT-801), an investigational glucagon-like ... 910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450Aug 25, 2020 · The studies were conducted as part of Altimmune’s ongoing collaboration with the University of Alabama at Birmingham (UAB). The latest study showed potent stimulation of antigen-specific CD4+ and CD8+ T cells in the lungs of CD-1 mice as early as 10 days following a single intranasal vaccination, with responses strongly biased toward CD8+ T ... Altimmune Inc, 910 Clopper Road Suite 201S, Gaithersburg, MD 20878 (240) 654-1450 [email protected]. Investors. Richard Eisenstadt Chief Financial OfficerAltimmune expects to commence patient enrollment in the Phase 1 clinical trial in the coming week. “We believe deployment of intranasal vaccines like AdCOVID will be essential to a successful global response to the pandemic,” said Vipin K. Garg, President and Chief Executive Officer of Altimmune. “FDA clearance of the IND marks an ...Five months after the FDA put its intranasal COVID-19 vaccine trial on hold, Altimmune is ditching the candidate after early trial results disappointed. | After not-so-promising results from a ...Track Altimmune Inc (ALT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Altimmune, Inc. Analyst Report: Johnson & Johnson Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and ...Jun 23, 2023 at 8:30 AM CEST. Oral Presentation: OS-063 Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Presenter: Stephen A. Harrison, MD ...Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.Mar 31, 2023 · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. Automatically receive Altimmune, Inc. financial information by e-mail. Subscribe. 910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450. Nav ALTIMMUNE. Altimmune anticipates having a data readout from this Phase 1 trial in Q2 2021. While traditional vaccines delivered by an intramuscular injection can stimulate systemic immunity as measured in the blood, they have not been shown to induce mucosal immunity in the nasal cavity, which may be critical for blocking transmission of the virus.President and Chief Executive Officer. Dr. Garg currently serves as our President and CEO and is a member of the board of directors. He joined Altimmune in November 2018 with over three decades of experience in the biotechnology and pharmaceutical industries. He has a proven track record of building and managing both private and publicly traded ...Chief Medical Officer. Scott Harris has served as Chief Medical Officer of Altimmune since 2019. He has 20 years of experience of development in gastroenterology, hepatology and metabolism therapeutics. He co-founded Lyric Pharmaceuticals in 2015, where he raised a $20.8 M Series A financing round and served as its Chief Medical Officer.Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX ...Aug 16, 2023 · Automatically receive Altimmune, Inc. financial information by e-mail. Subscribe. 910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450. Nav ALTIMMUNE. Approximately 50% of subjects achieved 10% weight loss or more and about 20% reached 15% weight loss or more. The safety trial showed 7.7% weight loss at week 12. President and CEO of Altimmune ...Sep 30, 2022 · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. mazda financial login
Jul 13, 2020 · Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and intranasal vaccines. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), an intranasal immune modulating treatment for COVID-19 (T ... GAITHERSBURG, Md., May 10, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a preclinical study of AdCOVID in a SARS-CoV-2 challenge model of infection. In this study, a single intranasal dose of AdCOVID provided sterilizing immunity in the lungs of ...Altimmune anticipates having a full data readout from this Phase 1 study in Q2 2021. “The commencement of our Phase 1 clinical trial of AdCOVID is an important milestone for our company and the global healthcare community in our fight against the SARS-CoV-2 virus,” said Dr. Scott Harris, Chief Medical Officer of Altimmune. “We believe ...Sep 12, 2023 · Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. ALTIMMUNE HIGHLIGHTS. Developing next generation peptide therapeutics for obesity and liver diseases. Multiple near-term value-driving catalysts in both obesity and NASH. $160M cash, cash equivalents and . short-term investments at 6/30/2023. 3Altimmune believes the treatment of obesity is the cornerstone of treating NASH and the principal morbidities of NASH. Glucagon increases energy expenditure and adipose tissue browning and works synergistically with GLP-1 to facilitate greater degrees of weight loss than GLP-1 alone.Altimmune believes the treatment of obesity is the cornerstone of treating NASH and the principal morbidities of NASH. As observed in a well-established preclinical model of the disease, ALT-801 was capable of inducing significantly greater weight loss compared to semaglutide, a GLP-1 receptor agonist, along with significantly greater decreases ...Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and intranasal vaccines. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), an intranasal immune modulating treatment for COVID-19 (T ...Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product ...chinatiems
Chief Medical Officer. Scott Harris has served as Chief Medical Officer of Altimmune since 2019. He has 20 years of experience of development in gastroenterology, hepatology and metabolism therapeutics. He co-founded Lyric Pharmaceuticals in 2015, where he raised a $20.8 M Series A financing round and served as its Chief Medical Officer. Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product ... Altimmune, Inc. ( ALT Quick Quote ALT - Free Report) , a clinical-stage company, announced completing the dosing of patients in a phase II study, evaluating the safety and efficacy of lead...Altimmune is also initiating scale up of manufacturing of its AdCOVID vaccine for advanced clinical trials and commercial production. The Company is actively engaged in discussions with additional strategic manufacturing partners with the goal of producing at least 100 million doses of AdCOVID in 2021.Mar 31, 2023 · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. Mar 21, 2023 · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product ... Approximately 50% of subjects achieved 10% weight loss or more and about 20% reached 15% weight loss or more. The safety trial showed 7.7% weight loss at week 12. President and CEO of Altimmune ...Find the latest Altimmune, Inc. (ALT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Dr. Sayare was appointed to the company’s board of directors in April 2010 and served as chairman of the board since January 2018. Most recently, he served as chairman and chief executive officer of ImmunoGen, a publicly traded biotechnology company engaged in the research and development of antibody-based cancer therapeutics. During his ... san antonio maps
Get the latest Altimmune Inc (ALT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Altimmune is also initiating scale up of manufacturing of its AdCOVID vaccine for advanced clinical trials and commercial production. The Company is actively engaged in discussions with additional strategic manufacturing partners with the goal of producing at least 100 million doses of AdCOVID in 2021.Jun 23, 2023 at 8:30 AM CEST. EASL International Liver Congress™ 2023. Oral Presentation: OS-063 Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial.Sep 28, 2021 · This morning, Altimmune revealed 12-week data from a phase 1 clinical trial with the company's lead candidate, pemvidutide, formerly known as ALT-801. This is a dual glucagon-like peptide-1 (GLP-1 ... In October 2020, she joined Altimmune, and currently serves as the functional lead for the pemvidutide and HepTcell clinical development programs. She maintains a clinical practice in infectious diseases as a volunteer at the Veterans Affairs Medical Center Hospital located in Washington, DC. Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's ... Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide (formerly ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.Five months after the FDA put its intranasal COVID-19 vaccine trial on hold, Altimmune is ditching the candidate after early trial results disappointed. | After not-so-promising results from a ... Jun 23, 2023 at 8:30 AM CEST. Oral Presentation: OS-063 Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Presenter: Stephen A. Harrison, MD ...Jul 11, 2023 · JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Altimmune ( ALT – Research Report) today and set a price target of $15.00. The company’s shares closed yesterday at $3.38 ... GAITHERSBURG, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of pemvidutide in subjects with obesity or overweight.Altimmune anticipates having a full data readout from this Phase 1 study in Q2 2021. “The commencement of our Phase 1 clinical trial of AdCOVID is an important milestone for our company and the global healthcare community in our fight against the SARS-CoV-2 virus,” said Dr. Scott Harris, Chief Medical Officer of Altimmune. “We believe ...This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing ofAltimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX ...April 1, 2021 at 7:00 AM EDT. GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield ...Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product ...Jan 4, 2023 · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. xin li
Dr. Roberts has served as the chief scientific officer (CSO) for Altimmune since December 2012. He has two decades of experience managing scientific operations – leading small molecule and biologics research and drug development efforts with a focus on viral vectors and antiviral therapies. Prior to joining Altimmune, Dr. Roberts served as ...This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight. Top line 48-wk results in Q4 2023. Altimmune is also initiating scale up of manufacturing of its AdCOVID vaccine for advanced clinical trials and commercial production. The Company is actively engaged in discussions with additional strategic manufacturing partners with the goal of producing at least 100 million doses of AdCOVID in 2021.Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), an intranasal immune modulator for COVID-19 (T-COVID™) and intranasal ...Jun 23, 2023 at 8:30 AM CEST. EASL International Liver Congress™ 2023. Oral Presentation: OS-063 Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial.Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product ...Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.Altimmune believes the treatment of obesity is the cornerstone of treating NASH and its co-morbidities and views these conditions as significant unmet medical needs. About HepTcell HepTcell is a novel immunotherapeutic comprised of nine synthetic peptides representing conserved hepatitis B (HBV) sequences formulated with IC31®, a TLR9-based ...Mar 31, 2023 · This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing of Altimmune recently started a Phase 1 clinical trial of AdCOVID and anticipates having a data readout from this trial in the second quarter of 2021. About Altimmune. Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease.Mar 21, 2023 · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide (formerly ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. Feb 17, 2021 · Altimmune expects to commence patient enrollment in the Phase 1 clinical trial in the coming week. “We believe deployment of intranasal vaccines like AdCOVID will be essential to a successful global response to the pandemic,” said Vipin K. Garg, President and Chief Executive Officer of Altimmune. “FDA clearance of the IND marks an ... Prior to joining Altimmune, Dr. Georges co-founded Immune Targeting Systems (ITS) Limited and served as the chief technology officer from 2004 until its acquisition by Altimmune in March 2015. Prior to ITS, Dr. Georges served as the of head of immunology at SEDAC-Therapeutics from 1999 until 2003. He received his Ph.D. in Molecular Immunology ...touchchatAltimmune anticipates having a full data readout from this Phase 1 study in Q2 2021. “The commencement of our Phase 1 clinical trial of AdCOVID is an important milestone for our company and the global healthcare community in our fight against the SARS-CoV-2 virus,” said Dr. Scott Harris, Chief Medical Officer of Altimmune. “We believe ...Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of ...Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.Sep 12, 2023 · Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.Jul 13, 2020 · Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and intranasal vaccines. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), an intranasal immune modulating treatment for COVID-19 (T ... Apr 1, 2022 · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. 910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450 Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.On June 1, Altimmune announced that the U.S. Food and Drug Administration (FDA) authorized the Company to proceed with a clinical trial of T-COVID, which is based on the same technology supporting Altimmune’s intranasal vaccine candidates, including AdCOVID for COVID-19, NasoShield for anthrax and NasoVAX for influenza. T-COVID is ...Mar 1, 2023 · ALTIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware. 20-2726770 (State or other jurisdiction of. incorporation or organization) (I.R.S. Employer. Identification No.) 910 Clopper Road, Suite 201S, Gaithersburg, MD. 20878 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including ... Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases.Five months after the FDA put its intranasal COVID-19 vaccine trial on hold, Altimmune is ditching the candidate after early trial results disappointed. | After not-so-promising results from a ...thinkorswim paper trading
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.José has served as chief business officer to Altimmune since July of 2018. He has more than two decades of experience structuring, negotiating and completing complex and accretive transactions including joint ventures, partnerships, mergers, acquisitions, debt financings, licensing and restructurings in a broad range of industries.A new obesity treatment being developed by Altimmune met goals for weight loss in a mid-stage clinical trial, but the data showed it doesn’t have a leg up on other popular drugs on the market ...Sep 28, 2021 · Altimmune to host a conference call today at 8:30 am EST GAITHERSBURG, Md. , Sept. 28, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemvidutide (proposed INN, formerly known as ALT-801), an investigational glucagon-like ... Altimmune ( NASDAQ: ALT) has made great progress in advancing several clinical products in its pipeline. In particular, it had already released results from its phase 2 MOMENTUM study, which used ...Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.Sep 12, 2023 · Business Description. Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non ... This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight. Top line 48-wk results in Q4 2023.This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing ofWhat is Pemvidutide Pemvidutide is a novel, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).Mr. Jordt is an accomplished executive with over 25 years of experience in the pharmaceutical industry. He joined Altimmune from Eli Lilly and Company, where he spent nearly two decades in various corporate and business development roles, most recently as Head of Transactions. During his tenure at Lilly, he led acquisitions, in/out-licensing ... shifts
Company Profile ALT. Business Description. Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics ...This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing of Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune’s COVID-19 Vaccine Candidate at its Houston Facility. GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has expanded its previously-announced AdCOVID manufacturing collaboration with ...Chief Medical Officer. Scott Harris has served as Chief Medical Officer of Altimmune since 2019. He has 20 years of experience of development in gastroenterology, hepatology and metabolism therapeutics. He co-founded Lyric Pharmaceuticals in 2015, where he raised a $20.8 M Series A financing round and served as its Chief Medical Officer. Mar 15, 2021 · Altimmune recently started a Phase 1 clinical trial of AdCOVID and anticipates having a data readout from this trial in the second quarter of 2021. About Altimmune. Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease.